Growing preclinical studies have shown that either intravenous or intracarotid artery administration of CD34 + effectively reduced the brain infarct volume and preserved the neurological function in both acute IS and chronic IS animal models [34–36]. This evidence concerns the gene CD34 and brain infarction.